SUPER HYPER GROWTH STOCKS: Pharmather (PHRM) (PHRRF) - RICH TV LIVE - Newscope Capital Corporation (CNSX:PHRM.CN) (OTCQB:PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. ("PharmaTher"), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, announced today the successful completion of a Type B pre-Investigational New Drug ("pre-IND") meeting with the U.S. Food and Drug Administration ("FDA") regarding PharmaTher's clinical development plan and its proposed Phase 2 clinical study for ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease ("LID-PD"). Based on the FDA's feedback from the written response meeting, the FDA confirmed that a 505(b)(2) regulatory pathway is acceptable, which allows for the potential to accelerate the clinical development for drug approval. In addition to responses of several aspects of the nonclinical and clinical development plan, the FDA was supportive of the proposed Phase 2 clinical study and the use of the Unified Dyskinesia Rating Scale score at three weeks as the primary efficacy endpoint. The FDA also recommended to include various efficacy and safety parameters and endpoints in the proposed Phase 2 clinical study to support future pivotal clinical trials, also known as 'registration studies' used by regulatory authorities to evaluate a drug's safety and efficacy for commercial approval. Ketamine is an FDA-approved drug with a known safety profile. PharmaTher entered into an exclusive license agreement with the University of Arizona to develop and commercialize ketamine to treat Parkinson's disease and movement disorders. Study results from preclinical studies and case studies in Parkinson's disease patients from the University of Arizona have shown that low-dose sub-anesthetic ketamine infusion indicates tolerability, safety and the potential of long-term therapeutic benefit to reduce levodopa-induced dyskinesia, improve on time, and reduce depression. Parkinson's disease is a debilitating disorder that affects over 1 million people in the U.S. and more than 7 million people worldwide. There is currently no cure for Parkinson's disease, although some drug combinations are used to treat the disease symptoms. The global Parkinson's disease market is expected to grow from USD $5 billion in 2019 to USD $7.5 billion by the end of 2025 and it is estimated that the potential market opportunity for LID-PD to be over USD $3 billion in the U.S. alone. About PharmaTher Inc. PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (CNSX:PHRM.CN) (OTCQB:PHRRF), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, such as ketamine, for FDA ap ... https://www.youtube.com/watch?v=P5oSIxulguE

Aphria Exoding over 30% as predicted - RICH TV LIVE - AUGUST 2, 2019 - Aphria Inc. Announces 158% Increase In Adult-Use Sales And Profitable Fourth Quarter CNW Group - Thu Aug 1, 3:15PM CDT Reports Profitable Fourth QuarterRecord Net Revenue of $128.6 Million, Up 75% from Prior Quarter Revenue for Adult-use Cannabis of $18.5 Million, Up 158% from Prior QuarterProvides Fiscal Year 2020 Outlook Aphria Inc. ("Aphria" or the "Company") (TSX: APHA and NYSE: APHA) today reported its results for the fourth quarter and fiscal year ended May 31, 2019. All amounts are expressed in thousands of Canadian dollars, unless otherwise noted and except for per gram, kilogram, kilogram equivalents, and per share amounts. "It's a new day at Aphria. Our team's solid execution across key areas of our business resulted in strong adult-use revenue growth and a profitable fourth quarter," stated Irwin D. Simon. "Over the last six months, our organization identified immediate priorities to help generate substantial progress near-term and long-term. We built upon existing business fundamentals and capabilities, streamlined processes, strengthened governance, and focused on building brand awareness. Together, we have nurtured an entrepreneurial culture of accountability through data-driven decision-making for value creation in the global medical and adult-use cannabis industry. Today's Aphria has a stronger foundation for long-term growth and success." Key Operating Highlights -- Net revenue of $128.6 million in the fourth quarter, an increase of 75% from prior quarter and 969% from prior year. -- Revenue for adult-use cannabis of $18.5 million in the fourth quarter, up 158% from prior quarter. -- Net income of $15.8 million and adjusted EBITDA of $0.2 million in the fourth quarter. -- Adjusted EBITDA from cannabis operations of $1.9 million in the fourth quarter. -- Closed a 5.25% convertible senior notes offering for net proceeds of over US $335 million. -- Ended quarter with a strong balance sheet and liquidity, including $571 million of cash, cash equivalents and liquid marketable securities, to fund planned Canadian and International growth. -- Settlement of Green Growth Brands takeover bid resulting in $50 million cash received and an additional $39 million to be received in November. -- Planted more than 200,000 plants in the new expanded area of Aphria One cultivation. -- On-track for annual production capacity of 255,000 kilograms when all facilities are fully licensed. -- Granted the maximum amount of lots within the German tender process, a total of five, and is the only licensed producer in Germany with the permission to grow all three strains of medical cannabis approved by the German Federal Institute for Drugs and Medical Devices. -- Introduced a CBD-based nutraceutical product line for the German market. -- Enhanced the executive team with appointment of several key positions. Subsequent Events -- Signed on as a PAX Era brand partner for the PAX Era device and platform. -- Aphria's subsidiary Marigold Projects Jamaica Limited received a retail Herb House license from Jamaica's Cannabis Licensing Authority to open its first store at the Peter Tosh Square, Unit #51, Pulse Center, 38a Trafalgar Road, overlooking the Peter Tosh Museum in New Kingston, Jamaica. Key Financial Highlights Three months ended Three months ended Twelve months ended Twelve months ended May 31, 2019 May 31, 2018 May 31, 2019 May 31, 2018 Net revenue $128,568 $12,026 $237,110 $36,917 Gross profit $36,007 $18,212 $75,421 $40,887 Adjusted cannabis gross profit (1) $15,165 $9,468 $40,596 $27,912 Adjusted cannabis gross margin (1) 53.0% 78.7% 53.3% 75.6% Adjusted distribution gross profit (1) $12,274 $0 $19,805 $0 #RICHTVLIVE #APHRIA #STOCKMARKET ... https://www.youtube.com/watch?v=Yv6YMYP0Rfs